
Commentary|Articles|December 12, 2014
Toxicities Associated With PI3K Inhibitors
Author(s)Denise A. Yardley, MD
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
<<<







































